

## Special Issue

# Hepatitis Vaccines: Immunization, Effectiveness and Future Challenges

### Message from the Guest Editor

Viral hepatitis, or inflammation of the liver, is caused by a viral infection and remains a major human health problem worldwide. Many different viruses cause viral hepatitis, which includes, in alphabetical order, hepatitis A, B, C, D, and E. WHO's global hepatitis strategy aims to reduce new hepatitis infections by 90% and deaths by 65% between 2016 and 2030. To reduce the morbidity and mortality, protective vaccination for these hepatitis viruses remains the main goal of public health policy and is a key component of the global viral hepatitis elimination plan. With this aim, in this Special Issue, we will summarize the current knowledge and aim to answer some of the many questions on viral hepatitis, their prevention through vaccination, vaccine effectiveness, and future challenges in this field. We invite the submission of original research and review articles that cover any aspect of viral hepatitis, prevention through vaccines, prophylactic and therapeutic vaccines, vaccine development and technology, vaccine immunity, etc.

### Guest Editor

Dr. Muhammad Atif Zahoor

Toronto Centre for Liver Disease, Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada

### Deadline for manuscript submissions

closed (30 September 2024)



## Vaccines

an Open Access Journal  
by MDPI

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/si/189962](https://mdpi.com/si/189962)

*Vaccines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)

[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)





# Vaccines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.4  
CiteScore 9.9  
Indexed in PubMed



[mdpi.com/journal/  
vaccines](https://mdpi.com/journal/vaccines)



## About the Journal

### Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

---

### Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College  
Roosevelt, 4331 CB Middelburg, The Netherlands

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /  
CiteScore - Q1 (Pharmacology (medical))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).